BACKGROUND: Ticagrelor is a P2Y12 inhibitor used to reduce thrombotic events in patients with acute coronary syndromes (ACS). The optimal dose of ticagrelor is crucial to prevent bleeding and thrombosis in ACS patients Therefore, we developed a pooled model-based meta-analysis of the population pharmacokinetics of ticagrelor by incorporating modeling results from previous ticagrelor-related population pharmacokinetics studies. METHOD: Studies of population pharmacokinetics of ticagrelor were searched using Pubmed. Patient population and drug concentration simulation results were extracted from the modeling data using Mrgsolve R package. RESULTS: A total of 1000 patients’ data were simulated from 2 published population pharmacokinetics studies. Ticagrelor and its metabolite were best described by the one-compartment model with the parent-metabolite model. The typical population parameter estimates of absorption rate constant (ka), clearance (CL/F), and apparent volume of distribution (V/F) were 0.801h−1, 13.9L/h and 297L respectively. The final pharmacokinetic parameters of AR-C124910XX were as follows: CLM/F = 8.67L/h; VM/F = 8.53L; Increased clearances of both parent drug and metabolite were observed in smoking patients. And clearance in female was lower than that in males. CONCLUSION: This model-based meta-analysis can contribute a better population pharmacokinetics model of ticagrelor in acute coronary syndromes patients.